Former Chief Medical Officer and Head of Development · Lyell Immunopharma, Inc. (LYEL)

Tina Albertson

FY2023 is the first fiscal year CompBrief holds for Tina Albertson as a named executive officer of Lyell Immunopharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,391,403

Salary $473,444Stock awards $0Bonus $42,097

5th of 6 named executive officers at Lyell Immunopharma by FY2023 total.

6 named officers on file for Lyell Immunopharma, FY2023

Tina Albertson’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • LYEL’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Lyell Immunopharma’s whole pay program stands against its peers

  • Lyell Immunopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LYEL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2024 (DEF 14A).

Free

Get Tina Albertson’s full pay file as a PDF — free

More than this page: up to 10 years of Tina’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Tina Albertson compensation by year

Lyell Immunopharma Summary Compensation Table · the one fiscal year held
In US dollars, as Lyell Immunopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$473,444
Bonus$42,097
Stock awards$0
Option awards$1,149,820
Non-equity incentive$0
Pension and deferred compensation$0
All other$726,042
Total$2,391,403

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lyell Immunopharma, Inc. DEF 14A filed April 22, 2024, accession 0001140361-24-021008, and prior-year filings.

How this page was built: the Lyell Immunopharma, Inc. filed document, accession 0001140361-24-021008. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2024.

Lyell Immunopharma’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Charles NewtonChief Financial Officer$4,317,424
Matthew LangChief Business Officer$4,008,353
Stephen HillChief Operating Officer$3,108,128
Lynn SeelyPresident, Chief Executive Officer and Director$2,647,476
Tina Albertson · this pageFormer Chief Medical Officer and Head of Development$2,391,403
Gary LeeChief Scientific Officer$2,226,356

The full Lyell Immunopharma compensation record

free company brief

This page is one person within Lyell Immunopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lyell Immunopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Tina Albertson's compensation dossier · One-time report. No refunds.